PGIM Jennison Health Sciences Fund - Class C (PHLCX)
Fund Assets | 1.68B |
Expense Ratio | 1.96% |
Min. Investment | $1,000 |
Turnover | n/a |
Dividend (ttm) | 5.25 |
Dividend Yield | 41.45% |
Dividend Growth | 174.48% |
Payout Frequency | Annual |
Ex-Dividend Date | Dec 20, 2024 |
Previous Close | 12.60 |
YTD Return | 1.28% |
1-Year Return | 8.49% |
5-Year Return | 96.56% |
52-Week Low | n/a |
52-Week High | n/a |
Beta (5Y) | 0.69 |
Holdings | 49 |
Inception Date | Jun 30, 1999 |
About PHLCX
The Fund's investment strategy focuses on Health/Biotech with 1.85% total expense ratio. The minimum amount to invest in Prudential Sector Funds, Inc: PGIM Jennison Health Sciences Fund; Class C Shares is $1,000 on a standard taxable account. Prudential Sector Funds, Inc: PGIM Jennison Health Sciences Fund; Class C Shares seeks long-term capital appreciation. PHLCX invests primarily in equity-related securities of U.S. firms engaged in the following industries: hospitals, nursing and residential care, health and medical insurance carriers, pharmaceutical and medicine companies, and medical equipment firms.
Performance
PHLCX had a total return of 8.49% in the past year. Since the fund's inception, the average annual return has been 13.38%, including dividends.
Top 10 Holdings
51.61% of assetsName | Symbol | Weight |
---|---|---|
Eli Lilly and Company | LLY | 13.44% |
UnitedHealth Group Incorporated | UNH | 5.29% |
Boston Scientific Corporation | BSX | 5.00% |
Neurocrine Biosciences, Inc. | NBIX | 4.56% |
argenx SE | ARGX | 4.46% |
Vertex Pharmaceuticals Incorporated | VRTX | 4.17% |
Intuitive Surgical, Inc. | ISRG | 4.17% |
AstraZeneca PLC | AZN | 3.63% |
Bristol-Myers Squibb Company | BMY | 3.58% |
Novo Nordisk A/S | NVO | 3.33% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Dec 20, 2024 | $5.25148 | Dec 20, 2024 |
Dec 20, 2023 | $1.91322 | Dec 20, 2023 |
Dec 20, 2022 | $0.61624 | Dec 20, 2022 |
Dec 20, 2021 | $14.02528 | Dec 20, 2021 |
Dec 20, 2019 | $1.43164 | Dec 20, 2019 |
Dec 20, 2018 | $4.77761 | Dec 20, 2018 |